Comparative Pharmacology
Head-to-head clinical analysis: DEPOCYT versus SARCLISA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPOCYT versus SARCLISA.
DEPOCYT vs SARCLISA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
None Documented
None Documented
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Category C
Category C
Antineoplastic
Monoclonal Antibody, Antineoplastic